Health Care Select Sector SPDR Fund (XLV)…

Home

Daily Stock Opinions and Ratings

Health Care Select Sector SPDR Fund (XLV)

161.42

-2.32 (1.42%)

as of Jul 6, 2026, 3:33:57 pm Market Open.

87 watching

Investor Insights

Jul 6, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

The Health Care Select Sector SPDR Fund (XLV) is currently experiencing a mix of opinions among experts. While some believe that healthcare stocks can provide a short-term alpha opportunity, particularly in light of recent market shifts and emerging drugs like GLP-1s, others view the sector as a potential value trap due to its underperformance this year. Despite concerns over high valuations and potential inflation, experts suggest that healthcare remains a solid investment due to its insulation from interest rate volatility. One expert emphasizes the strategic focus on healthcare equipment and services as an alternative for those wary of political influences on pharmaceuticals. Overall, healthcare is anticipated to remain a buy for the long term, particularly as the sector may rebound in upcoming years.

Consensus

Buy

Valuation

Undervalued

Similar

IHI

BUY

She hopes healthcare picks up in the second half. She feels we're in late cycle where staples and utilities are expensive, but healthcare performs the best among these. HC has underperformed in the first half, but should improve second half or 2024, because XLV holds so many good companies.

BUY

She expects a recession in 2024, and higher unemployment. She sees a lot of opportunity in healthcare.

TOP PICK

Defensive name that provides exposure to health care sector.
Very strong sector as health care demand not going away.
Excellent prospects for healthcare during summer months.

BUY

She's not a fan of ETFs, this single-brushstroke style of investing, but an ETF makes sense in health care, because the companies are very different. Some will excel while others will flame out (considering their drug pipelines).

BUY

As a 5-year hold The valuation is attractive, balance sheet is good and there's non-discretionary demand for the products. Many of the underlying stocks pay a good dividend.

BUY

Is bullish biotech Biotchechs like Insight are up 13%, Moderna 25% and Regeneron 6% so hitting their lows. The whole XLV is up 8.5% off its June 17 low. 91 stocks in the S&P are above their 200-day moving average, and 18 of these are healthcare. This is the best sector to be overweight in.

BUY

Healthcare thrives when economies slow.

BUY

Allan Tong’s Discover Picks XLV ETF’s top holdings are Johnson & Johnson, UnitedHealth Group, Pfizer, Abbott Labs, AbbVie, Thermo Fisher, Merck, Eli Lilly and Danaher. A bullish case can be made for almost all all these names. Another plus: the MER is only 0.1%, though the dividend pays a lowly 1.4%. XLV’s PE is merely 6.62%, volumes average a healthy 14.8 billion a day, and its beta is a very stable 0.73. While you can make better gains holding some of the stocks this ETF holds, XLV is a safe way to play the American healthcare stocks in 2022. Read 3 Promising Healthcare Stocks for our full analysis.

BUY

He likes healthcare, given the return to preventative care and elective surgeries. Also, there's a strong pharma pipeline. Stay long in health.

BUY

Allan Tong’s Discover Picks However, if you want to own several in one place or can’t afford to buy one of these stocks individually, XLV is the place to go. It trades on the Nasdaq. It charges an ultra-low MER of 0.12%, trades at merely 4.18x PE and pays a 1.4% dividend. Also, average volumes are a robust 13.9 million and the Beta is a low 0.71. YTD, XLV has lost 7.55%, but Omicron was the major disruptor and restrictions are quickly lifting now. Essentially, you’re buying this ETF for the future. Read 3 Best Cyclical and Value ETFs for our full analysis.

BUY

Healthcare stock with a 5-year horizon? She prefers owning individual names, but XLV includes Thermo-Fisher, BMO, Abbott, etc. Healthcare will change a lot in coming years, and XLV gives you a good representation.

BUY

XLV vs. IBB Has done very well, and also well positioned for the type of market we're in right now. Cap weighted. A fine way to get pure beta in the sector. A better choice than IBB. IBB is much more concentrated with a higher risk in biotech. Smaller caps have lagged large caps since last year, to the tune of 50-60% relative performance, because of the impact of higher interest rates on growth, plus the FDA's become slower to approve new drugs.

PAST TOP PICK

(A Top Pick May 05/21, Up 14%) Recently pulled up again, with defensive sectors doing quite well. He sold in October. Longer term, in 2022, healthcare will be a good sector to be in. Put it on the back burner for now, and take a look again in May.

BUY

Long-term, really likes the sector. When things are hot, the sector may lag. XLV has about 65 names. Aging demographics, growing emerging markets and middle class, increased healthcare spending. This year, healthcare ranks #8 out of 11 sectors. But if you're concerned about the long term, which he thinks you should be, XLV is a good place to start.

DON'T BUY

Better to buy the holdings? He doesn't buy ETFs, because he's an active manager. He'd rather buy the individual stocks, and he doesn't know what's in this ETF, though Thermo-Fisher, a key holding, is a fine company. In this sector, he owns Anthem, Abbvie and CVS, for example. Healthcare isn't in the sun now, but you can do well if you pick the right stocks.

Showing 16 to 30 of 64 entries

Most Recent Experts

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Kevin Simpson

Capital Wealth Planning

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephanie Link, Chief investment strategist, Hightower

Hightower

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Health Care Select Sector SPDR Fund (XLV)